This achievement was made possible through the collective efforts of the VeloSano community, including participants in the annual Bike to Cure event and Trike & Bike community rides, as well as donors who made direct contributions or legacy gifts to the fund.
The total amount was announced in a video celebrating the dedication of everyone involved in VeloSano’s efforts throughout 2024. Since its inception in 2014, more than $80 million has been raised for cancer research at Cleveland Clinic and Cleveland Clinic Children’s. VeloSano began with a weekend event and has evolved into an initiative that engages individuals, families and organizations throughout the year.
“Over the last 30 years, the American Cancer Society reports more than 4 million lives here in the U.S. have been saved due to cancer advances,” said Alex A. Adjei, M.D., Ph.D., Chief of Cleveland Clinic Cancer Institute. “The support we receive through VeloSano enables Cleveland Clinic to expand our work in cancer research to help add to that number and move toward not just saving lives but one day finding a cure for cancer.”
A portion of VeloSano funds is awarded through a competitive application process as VeloSano Pilot Grants. Since 2014, over 240 cancer research projects have been funded and an additional $85 million has been earned from extramural granting sources, making the total impact of VeloSano more than $165 million. Additionally, funding has supported the training of high school students, college students and postdoctoral fellows to ensure future generations continue the research to conquer cancer.
Fundraising activity peaks during VeloSano Bike to Cure weekend each September. We are grateful to the long-time support of the event’s partners– Founding Partners: the Cleveland Guardians and the Kohl Fund; Supporting Partners: Adcom, Jones Day, and Lexus; and Contributing Partners: Amgen, AstraZeneca, BeiGene, Genentech, Gilead Oncology, Global Prairie, KeyBank, Michelob Ultra, Novartis, Petitti Garden Centers, Pfizer, The Lerner Foundation, and TransDigm Group.
100% For The Cure
